Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study

Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study

Abstract Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) increase haemoglobin and haematocrit levels, potentially causing secondary erythrocytosis—defined as a haemoglobin level above 16.5 g/dL in men and 16.0 g/dL in women—which is associated with an elevated thromboembolic risk. This...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdullahi Ahmed Mohamed, Camilla Fuchs Andersen, Daniel Mølager Christensen, Lise Da Riis-Vestergaard, Milan Mohammad, Mariam Elmegaard, Casper Binding, Christian Torp-Pedersen, Tor Biering-Sørensen, Morten Lock Hansen, Lars Køber, Andreas Glenthøj, Jesper Jensen, Charlotte Andersson, Morten Schou, Gunnar Gislason
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Cardiovascular Diabetology
Subjects:
SGLT2 inhibitors
Erythrocytosis
Heart failure with reduced ejection fraction
Thromboembolism
Online Access:https://doi.org/10.1186/s12933-025-02871-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12933-025-02871-w

Similar Items